No profile data available.
Insight Molecular Diagnostics Inc. (IMDX) is a healthcare company in the medication development research industry, based in Nashville, United States, with about 55 full-time employees.
It reported revenue of $4.06 million for fiscal year 2025, up 115.6% from fiscal year 2024, and net income of -$50.22 million. UNITED STATES was its largest region in fiscal year 2025, with 99% of revenue. Its market capitalization was $110.28 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests.
Insight Molecular Diagnostics reported $4.06 million in revenue for fiscal year 2025, up 115.6% from $1.88 million in fiscal year 2024.
UNITED STATES: 99% of revenue by region in fiscal year 2025, followed by Europe (1%).
$110.28 million as of October 9, 2026.
Listed companies of a similar size in the same industry (medication development research) include Evotec SE (EVO), C4 Therapeutics, Inc. (CCCC), Molecular Partners AG (MOLN), MindWalk Holdings Corp. (HYFT).